These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 34871053)

  • 21. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915-918.
    Gando A; Alexay S; Galán Núñez JP; Cano LN; Diez RA; Costa LA
    J Med Virol; 2021 May; 93(5):2626-2627. PubMed ID: 33590886
    [No Abstract]   [Full Text] [Related]  

  • 24. Spontaneous Muscle Hematoma in Japanese Patients with Severe COVID-19 Treated with Unfractionated Heparin: Two Case Reports.
    Ito Y; Awano N; Uchiyama F; Inomata M; Kuse N; Tone M; Takada K; Fujimoto K; Muto Y; Sagisaka S; Maki K; Yamashita R; Harada A; Nishimura JI; Hayashi M; Izumo T
    Intern Med; 2021 Nov; 60(21):3503-3506. PubMed ID: 34433713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venous thromboembolism in non-critically ill patients with COVID-19 infection.
    Trimaille A; Curtiaud A; Marchandot B; Matsushita K; Sato C; Leonard-Lorant I; Sattler L; Grunebaum L; Ohana M; Von Hunolstein JJ; Andres E; Goichot B; Danion F; Kaeuffer C; Poindron V; Ohlmann P; Jesel L; Morel O
    Thromb Res; 2020 Sep; 193():166-169. PubMed ID: 32707275
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).
    Irfan N; Chagla Z
    Ann Intern Med; 2021 May; 174(5):JC50. PubMed ID: 33939483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adequate anticoagulation and ECMO therapy in COVID-19 patients with severe pulmonary embolism.
    Gaisendrees C; Walter SG; Elderia A; Vollmer M; Kaya S; Djordjevic I; Eghbalzadeh K; Sabashnikov A; Kahlert HA; Deppe AC; Böll B; Madershahian N; Wahlers T
    Perfusion; 2021 Sep; 36(6):575-581. PubMed ID: 33280533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis.
    Moll M; Zon RL; Sylvester KW; Rimsans J; Chen EC; Ghosh AJ; Abston E; Kim A; Rutherford H; Mitre X; Hakim A; Connell NT; Battinelli E; Fredenburgh LE; Baron RM; Hobbs BD; Cho MH; Mittleman MA; Woolley AE; Connors JM
    Thromb Res; 2021 Jul; 203():57-60. PubMed ID: 33940309
    [No Abstract]   [Full Text] [Related]  

  • 29. In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.
    Sacks HS
    Ann Intern Med; 2022 Apr; 175(4):JC40. PubMed ID: 35377719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Best practice statements and recommendations for caring for critically ill patients with COVID-19.
    Dugar SP; Vallabhajosyula S
    Ann Intern Med; 2020 Jun; 172(12):JC62. PubMed ID: 32539521
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [COVID-19, anticoagulation and venous thromboembolism: what have we learned ?].
    Blondon M; Robert-Ebadi H
    Rev Med Suisse; 2021 Dec; 17(762):2140-2144. PubMed ID: 34878743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COVID-19 in the Critically Ill: Too Risky for High-Dose Anticoagulation?
    Paez Vargas JJ; Vidal González A; Pérez-Calvo C; Flandes J
    Chest; 2021 Aug; 160(2):e249. PubMed ID: 34366058
    [No Abstract]   [Full Text] [Related]  

  • 33. Intensity of anticoagulation and survival in patients hospitalized with COVID-19 pneumonia.
    Hsu A; Liu Y; Zayac AS; Olszewski AJ; Reagan JL
    Thromb Res; 2020 Dec; 196():375-378. PubMed ID: 32980620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A COVID-19 patient with recurrent acute limb ischaemia despite two successive types of therapeutic dose anticoagulation and thrombolysis.
    Teng E; Pignanelli M; Hammad F; Wisa D
    BMJ Case Rep; 2021 Aug; 14(8):. PubMed ID: 34389601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5 classes of antihypertensive drugs were not linked to positive COVID-19 test results or severe COVID-19.
    Fekete T
    Ann Intern Med; 2020 Sep; 173(6):JC35. PubMed ID: 32926815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.
    Yang P; Tekwani S; Martin GS
    Ann Intern Med; 2020 Jun; 172(12):JC63. PubMed ID: 32539520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic anticoagulation in COVID-19 patients.
    Belfaqeeh O; Patel J; Janapala RN; Pourmand A
    Thromb Res; 2021 Dec; 208():213. PubMed ID: 33610333
    [No Abstract]   [Full Text] [Related]  

  • 38. Therapeutic Anticoagulation with Heparin in Patients with Covid-19.
    Fernandes TM; McGuire WC; Morris TA
    N Engl J Med; 2021 Nov; 385(21):2013. PubMed ID: 34788515
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic Anticoagulation with Heparin in Patients with Covid-19.
    Sterpetti AV
    N Engl J Med; 2021 Nov; 385(21):2013-2014. PubMed ID: 34788516
    [No Abstract]   [Full Text] [Related]  

  • 40. The Need for Chemo-Thromboprophylaxis Protocols in Critically Ill COVID-19 Patients.
    Ehrlich H; McKenney M; Elkbuli A
    Am Surg; 2021 May; 87(5):698-699. PubMed ID: 33283541
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.